Exagen (NYSE:XGN) released its earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.10, MarketWatch Earnings reports.
Shares of Exagen stock opened at $12.70 on Thursday. The business has a fifty day moving average of $18.52. Exagen has a 1 year low of $11.54 and a 1 year high of $29.86.
Several equities analysts have recently commented on the company. Zacks Investment Research lowered Exagen from a “hold” rating to a “sell” rating in a report on Wednesday, January 1st. Cantor Fitzgerald restated a “buy” rating and issued a $25.00 price target on shares of Exagen in a research report on Monday, March 2nd.
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
Read More: Stop Order
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.